BORTEZOMIB

Post-LOE

bortezomib

Gland Pharma

ANDAINTRAVENOUS, SUBCUTANEOUSINJECTABLE

Approved

Dec 2025

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

BORTEZOMIB (bortezomib) by Gland Pharma is proteasome inhibitors [moa]. Approved for myeloma, lymphoma, myeloma and 1 more indications. First approved in 2025.

Drug data last refreshed 19h ago

Mechanism of Action

Proteasome Inhibitors

Pharmacologic Class:

Proteasome Inhibitor

Indications (2)

myeloma lymphoma

Clinical Trials (20)

NCT07285239Phase 3Not Yet Recruiting

Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma

Started May 2026

500 enrolled

Multiple Myeloma

NCT07224672Phase 2Not Yet Recruiting

A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis

Started Mar 2026

60 enrolled

Amyloidosis

NCT06577025Phase 2Active Not Recruiting

A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma

Started Aug 2024

43 enrolled

Multiple Myeloma

NCT06353022Phase 2Active Not Recruiting

Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma

Started Jun 2024

103 enrolled

Multiple Myeloma

NCT06208150Phase 3Recruiting

A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide

Started Jan 2024

795 enrolled

Multiple Myeloma

Worked on BORTEZOMIB at Gland Pharma? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.